RxDoctor Payments Data

Melanie Taylor, MD

Neurology · Grand Rapids, MINPI 1134363419

Payments from drug & device makers

$149,958in general payments, 2019–2025

Across 125 payments — averaging $1199.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$42K
  • Mallinckrodt Enterprises LLC$40K
  • Biogen$39K
  • Tanabe Pharma America, Inc.$19K
  • UCB SA$7K
  • Catalyst Pharmaceuticals, Inc.$2K
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$10,76712%
  • Speaking & faculty fees$72,01879%
  • Travel & lodging$6,3987%
  • Food & beverage$1,8582%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$149,958 in reported general payments places this provider in the 90th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$24,615
Medicare patients
145
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50150$1,570,640
Radicava OrsEdaravone103$1,524,243
FirdapseAmifampridine Phosphate36$1,309,352
EvrysdiRisdiplam32$833,939
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5044$755,856
VyvgartEfgartigimod Alfa-Fcab22$682,299
PanzygaImmun Glob G(Igg)-Ifas/Glycine34$587,210
Gamunex-CImmune Globul G/Gly/Iga Avg 4638$436,208
SkyclarysOmaveloxolone12$387,212
RelyvrioSod Phenylbutyrat/Taurursodiol19$240,938
GammakedImmune Globul G/Gly/Iga Avg 4648$211,832
NuedextaDextromethorphan Hbr/Quinidine14$21,252
Mycophenolate Mofetil92$12,796
Pyridostigmine Bromide164$11,942
Gabapentin423$9,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$64$1,570,640150 claims
Catalyst Pharmaceuticals, Inc.Firdapse$2,100$1,309,35236 claims
Genentech USA, Inc.Evrysdi$22$833,93932 claims
Argenx US, Inc.Vyvgart$42,025$682,29922 claims
BiogenSkyclarys$39,017$387,21212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 neurology providers in Michigan.

Other neurology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →